Doctors often face tough choices when treating aggressive brain tumors. A recent trial looked at how well a drug called regorafenib works in newly diagnosed and recurring glioblastoma cases. Instead of traditional methods, researchers used a flexible approach where patient data influenced treatment
In Canada, researchers often submit applications to ethics boards before starting a study. These forms normally ask for basic details about the trial, but they rarely prompt investigators to think about who will benefit from the research or how patients will be involved in decisions. The study lo
Doctors in the U. S. now have another tool to fight a tough cancer. The FDA gave the green light for early use of an experimental pill called daraxonrasib. It targets pancreatic ductal adenocarcinoma, a fast-spreading form of pancreatic cancer that has already resisted other treatments. Patients who
Research on semaglutide, a once-a-week shot, shows it can help people lose noticeable weight—up to one-sixth of their body weight in some cases. Trials called STEP 1, 3, and 4 focused on adults without diabetes and found weight drops between ten and seventeen percent. For those with type 2 diabetes
For decades, drug testing followed the same slow rhythm. Researchers ran trials in stages, then paused for months to analyze data before asking regulators for the next step. Patients waited years for treatments while paperwork piled up. Now, a new FDA approach cuts out the waiting by letting regulat
Quick action saves lives when someone has a heart attack. That’s why some emergency teams now give aspirin on the spot. But does this practice hold up under real-world conditions? A study called CELEBRATE looked at whether early aspirin use actually helps patients before they even get to the hospita
Research shows people with conditions like schizophrenia or bipolar disorder often struggle with obesity at higher rates than the general public. Medications they take and daily habits can lead to weight gain over time. Experts believe this issue needs more attention, especially since mental health
A French biotech company just got a two-year break from paying back millions in loans, giving it more cash to push forward on cutting-edge research. The firm, known for developing treatments targeting tough diseases, reached a deal with lenders to delay loan payments totaling around €17. 8 million.
HIV remains a global health challenge, weakening the immune system by targeting key defense cells. Medication like antiretrovirals (ART) helps people live longer, but it doesn't always ease the emotional toll. Stress, anxiety, and depression often linger, making daily life harder. These issues might
After a stroke, many people struggle to regain control of their arms. Traditional rehab often feels repetitive and slow. But what if playing games could speed up the process? Researchers tested this idea by comparing two rehab methods for stroke survivors. One group used a simple video game system t
